chevron_leftBack
As of 24 April 2025, AB Science S.A. has a market cap of $105.88M USD, ranking #20413 globally and #287 in France. It ranks #2032 in the Healthcare sector, and #460 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$105.88MUSD
93.04M EUR
Enterprise Value
$117.07MUSD
102.88M EUR
Revenue (TTM)
$1.23MUSD
1.08M EUR
EBITDA (TTM)
-$9.77MUSD
-8.58M EUR
Net Income (TTM)
-$6.88MUSD
-6.04M EUR
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Alain Moussy
open_in_new
Employees
57
Founded
2001
Website
ab-science.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.8% | 0.4% | 2.6% | -21% | 48% | -29% |
Upcoming Earnings
Earnings Date
Wed, Apr 30
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AB
AB Science
ISIN: FR0010557264
Shares Out.:
Shares Outstanding:
57.83M1
Shares Float:
50.942M2
|
1.47 EUR | |
|
0Q77
AB Science
ISIN: FR0010557264
|
1.44 EUR | |
|
ABSCF
AB Science
ISIN: FR0010557264
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.57 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About AB Science S.A.
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
